NCT04510207已完成3 期
Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 44,101
- 试验地点
- 10
- 主要终点
- The incidence of COVID-19 cases after two-doses of vaccination
研究概览
简要总结
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above. The participants were randomized into three groups of investigational vaccine 1, investigational vaccine 2 and placebo in a 1:1:1 ratio.2 doses of the investigational vaccine or placebo are inoculated into the deltoid muscle of the either arm according to the vaccination schedule of D0 & D21 (+7 days).According to the immune durability results in Phase I/II study, and cross-neutralization assay results, a third dose (booster dose) generates a better immune response and is estimated to offer better protection, therefore, a booster dose will be given after 3 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects aged 18 years old and above.
- •By asking for medical history and physical examination, the investigator judged that the health condition is well.
- •Female subjects of childbearing age are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 3 months after enrolment. Effective contraceptive measures have been taken within 2 weeks before inclusion.
- •During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan.
- •With self-ability to understand the study procedures, the informed consent & voluntarily sign an informed consent form and be able to comply with the requirements of the clinical study protocol.
排除标准
- •Confirmed acute cases of SARS-CoV-2 Infection.
- •Have a history of SARS, MERS infection (self-report, on-site inquiry).
- •Positive urine pregnancy test result.
- •Fever (body temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination.
- •Axillary body temperature > 37.0 ℃ before vaccination.
- •Previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated SARS-CoV-2 vaccine have occurred.
- •Has a history of convulsion, epilepsy, encephalopathy or mental illness or family history.
- •With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
- •With severe liver diseases, severe kidney diseases defined as eGFR less than 60, uncontrollable hypertension (systolic blood pressure >150 mmHg, diastolic blood pressure > 90 mmHg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases.
- •Has been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases.
- •With known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, liver and kidney diseases, and malignant tumors.
- •Has a history of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation disease).
- •Receiving anti-TB therapy.
- •Patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days).
- •Live attenuated vaccine is inoculated within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination.
- •Received blood products within 3 months before this vaccination
- •Received other research drugs within 6 months before this vaccination.
- •Other circumstances judged by investigators that are not suitable for this clinical trial.
结局指标
主要结局
The incidence of COVID-19 cases after two-doses of vaccination
时间窗: From14 days after the second dose to 6 month after the second dose
The incidence of COVID-19 cases after the booster dose of immunization
时间窗: From 14 days after the booster dose
次要结局
- The incidence of severe cases of COVID-19 and deaths accompanied by COVID-19 after two-doses of vaccination(From 14 day after the booster dose)
- The incidence of any adverse reactions/events(28 days after each immunization)
- The incidence of serious adverse events (SAE)(From the beginning of the first dose to 12 months after the second immunization)
- The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody(14 days, 28 days and 6th month after the booster dose)
- The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody(14 days after full course of immunization)
- The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody(14 days, 28 days and 6th month after the booster dose)
- The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody(14 days, 28 days and 6th month after the booster dose)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT05975268Shanghai Junshi Bioscience Co., Ltd.747
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaPrimary Immune ThrombocytopeniaNCT04687072argenx207
已完成
3 期
Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeAcute Coronary SyndromeNCT03473223CSL Behring18,226
已完成
3 期
Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)HypercholesterolemiaNCT00413972Organon and Co392
招募中
3 期
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable AnginaChronic Stable Angina PectorisNCT03789552Tasly Pharmaceuticals, Inc.765